Riportiamo 10 articoli rilevanti del nostro gruppo sull’argomento relative agli ultimi 5 anni:
1. Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, Baron A, Park JW, Han G, Jassem J, Blanc JF, Vogel A, Komov D, Evans TRJ, Lopez C, Dutcus C, Guo M, Saito K, Kraljevic S, Tamai T, Ren M, Cheng AL. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018 Mar 24;391(10126):1163-1173. doi: 10.1016/S0140-6736(18)30207-1. PMID: 29433850. IF: 202.7
2. Gramantieri L, Gnudi F, Vasuri F, Mandrioli D, Fornari F, Tovoli F, Suzzi F, Vornoli A, D'Errico A, Piscaglia F, Giovannini C. Aflatoxin B1 DNA-Adducts in Hepatocellular Carcinoma from a Low Exposure Area. Nutrients. 2022 Apr 15;14(8):1652. doi: 10.3390/nu14081652. PMID: 35458213; PMCID: PMC9024438. IF: 5.7
3. Gramantieri L, Giovannini C, Suzzi F, Leoni I, Fornari F. Hepatic Cancer Stem Cells: Molecular Mechanisms, Therapeutic Implications, and Circulating Biomarkers. Cancers (Basel). 2021 Sep 10;13(18):4550. doi: 10.3390/cancers13184550. PMID: 34572776; PMCID: PMC8472624. IF: 6.6
4. Gramantieri L, Giovannini C, Piscaglia F, Fornari F. MicroRNAs as Modulators of Tumor Metabolism, Microenvironment, and Immune Response in Hepatocellular Carcinoma. J Hepatocell Carcinoma. 2021 May 12; 8: 369-385. doi: 10.2147/JHC.S268292. PMID: 34012928; PMCID: PMC8126872. IF: 4.9
5. D'Avola D, Granito A, Torre-Aláez M, Piscaglia F. The importance of liver functional reserve in the non-surgical treatment of hepatocellular carcinoma. J Hepatol. 2022 May;76(5):1185-1198. doi: 10.1016/j.jhep.2021.11.013. Epub 2021 Nov 15. PMID: 34793869. IF: 25
6. Gramantieri L, Pollutri D, Gagliardi M, Giovannini C, Quarta S, Ferracin M, Casadei-Gardini A, Callegari E, De Carolis S, Marinelli S, Benevento F, Vasuri F, Ravaioli M, Cescon M, Piscaglia F, Negrini M, Bolondi L, Fornari F. MiR-30e-3p Influences Tumor Phenotype through MDM2/TP53 Axis and Predicts Sorafenib Resistance in Hepatocellular Carcinoma. Cancer Res. 2020 Apr 15;80(8):1720-1734. doi: 10.1158/0008-5472.CAN-19-0472. Epub 2020 Feb 3. PMID:32015093. IF: 13.3
7. Giovannini C, Salzano AM, Baglioni M, Vitale M, Scaloni A, Zambrano N, Giannone FA, Vasuri F, D'Errico A, Svegliati Baroni G, Bolondi L, Gramantieri L. Brivanib in combination with Notch3 silencing shows potent activity in tumour models. Br J Cancer. 2019 Mar;120(6):601-611. doi: 10.1038/s41416-018-0375-4. Epub 2019 Feb 15. PMID: 30765875; PMCID: PMC6461893. IF: 7.6
8. Gramantieri L, Baglioni M, Fornari F, Laginestra MA, Ferracin M, Indio V, Ravaioli M, Cescon M, De Pace V, Leoni S, Coadă CA, Negrini M, Bolondi L, Giovannini C. LncRNAs as novel players in hepatocellular carcinoma recurrence. Oncotarget. 2018 Oct 12;9(80):35085-35099. doi: 10.18632/oncotarget.26202. PMID: 30416681; PMCID: PMC6205555. IF: 3.3
9. Piscaglia F, Granito A, Bolondi L. DAAs for HCV and risk of hepatocellular carcinoma: current standpoint. Lancet Gastroenterol Hepatol. 2018 Nov;3(11):736-738. doi: 10.1016/S2468-1253(18)30238-3. PMID: 30353852. IF: 45
10. Peter R Galle, Alejandro Forner, Josep M Llovet, Vincenzo Mazzaferro, Fabio Piscaglia, Jean-Luc Raoul, Peter Schirmacher, Valérie Vilgrain. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol. 2018 Jul;69(1):182-236. doi: 10.1016/j.jhep.2018.03.019. Epub 2018 Apr 5. IF: 25
Un elenco più esteso delle pubblicazioni più rilevanti relative alle attività di laboratorio può essere liberamente visualizzato qui:
https://pubmed.ncbi.nlm.nih[…]gramantieri+l&sort=date